Stock GNFT GENFIT S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genfit S.A. Nasdaq

Equities

GNFT

US3722791098

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 03:17:52 2024-07-11 pm EDT 		5-day change 1st Jan Change
4.345 USD -0.41% Intraday chart for Genfit S.A. +4.45% +12.86%
05:18pm European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
Jul. 08 European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 684.6 154.9 214.6 197 176 205.5 - -
Enterprise Value (EV) 1 591.4 169.6 30.1 131.8 168.4 204.2 173 165.6
P/E ratio -10 x -1.54 x 3.51 x -8.27 x -6.1 x 7.94 x -27.9 x 162 x
Yield - - - - - - - -
Capitalization / Revenue 16.7 x 20 x 2.51 x 7.42 x 4.61 x 2.49 x 4.24 x 2.11 x
EV / Revenue 14.4 x 21.9 x 0.35 x 4.96 x 4.41 x 2.48 x 3.57 x 1.7 x
EV / EBITDA -11.3 x -2.29 x 0.87 x -5.18 x -6.75 x 6.95 x 64.1 x 13.7 x
EV / FCF -11.9 x -1.74 x 0.3 x - -3.02 x 40 x 14.5 x 22.4 x
FCF Yield -8.41% -57.4% 330% - -33.2% 2.5% 6.88% 4.47%
Price to Book 8.16 x -9.5 x 2.55 x - 2.59 x 3.03 x 2.19 x 1.99 x
Nbr of stocks (in thousands) 38,785 38,811 49,727 49,655 49,712 49,759 - -
Reference price 2 17.65 3.992 4.316 3.968 3.540 4.050 4.050 4.050
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 40.96 7.758 85.58 26.57 38.18 82.48 48.49 97.48
EBITDA 1 -52.43 -74.03 34.56 -25.46 -24.93 29.4 2.7 12.1
EBIT 1 -57.83 -77.59 31.82 -27.29 -26.58 11.84 -21.2 41.5
Operating Margin -141.19% -1,000.12% 37.18% -102.72% -69.62% 14.36% -43.72% 42.57%
Earnings before Tax (EBT) 1 -65.72 -101.6 69.47 -23.84 -28.51 32.68 -22.6 22
Net income 1 -65.14 -101.2 67.26 -23.72 -28.89 28.44 -22.3 22.86
Net margin -159.04% -1,304.73% 78.59% -89.28% -75.69% 34.48% -45.99% 23.45%
EPS 2 -1.760 -2.600 1.230 -0.4800 -0.5800 0.5100 -0.1450 0.0250
Free Cash Flow 1 -49.71 -97.27 99.38 - -55.84 5.1 11.9 7.4
FCF margin -121.36% -1,253.82% 116.12% - -146.28% 6.18% 24.54% 7.59%
FCF Conversion (EBITDA) - - 287.57% - - 17.35% 440.74% 61.16%
FCF Conversion (Net income) - - 147.75% - - 17.93% - 32.37%
Dividend per Share 2 - - - - - - - -
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 35.6 5.867 1.891 3.428 82.15 12.19 14.38 15.37 22.8 48.27 46.15
EBITDA - - - - - - - - - - -
EBIT 1 -11.9 -49.16 -28.43 -29.55 61.37 -14.34 -12.94 -19.3 -7.281 21.08 8.598
Operating Margin -33.41% -837.96% -1,503.23% -862.05% 74.7% -117.69% -90.03% -125.53% -31.93% 43.67% 18.63%
Earnings before Tax (EBT) 1 -14.3 -53.17 -48.48 6.163 63.31 -10.36 -13.48 -20.44 -8.074 22.83 9.848
Net income 1 -14.01 -53.01 -48.21 9.058 58.2 -10.4 -13.32 -20.85 -8.04 17.22 13.1
Net margin -39.36% -903.55% -2,549.44% 264.24% 70.85% -85.32% -92.64% -135.64% -35.26% 35.68% 28.39%
EPS 2 -0.1200 - - - - - - -0.4200 - 0.4900 0.1200
Dividend per Share - - - - - - - - - - -
Announcement Date 4/8/20 9/30/20 4/1/21 9/29/21 4/7/22 9/28/22 4/13/23 9/20/23 4/4/24 - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 14.7 - - - - - -
Net Cash position 1 93.1 - 185 65.3 7.61 1.26 32.5 39.9
Leverage (Debt/EBITDA) - -0.1981 x - - - - - -
Free Cash Flow 1 -49.7 -97.3 99.4 - -55.8 5.1 11.9 7.4
ROE (net income / shareholders' equity) -124% -283% - -22.2% -35.6% 0.81% 1.5% 9.5%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 2.160 -0.4200 1.690 - 1.370 1.340 1.850 2.040
Cash Flow per Share 2 -1.290 -2.480 1.800 - -1.120 -0.2200 -0.7000 1.900
Capex 1 2.03 0.9 0.54 - 0.41 0.25 0.25 0.35
Capex / Sales 4.96% 11.6% 0.63% - 1.08% 0.3% 0.52% 0.36%
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genfit S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.05 EUR
Average target price
9.325 EUR
Spread / Average Target
+130.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+23.57% 45.01B
LONZA GROUP AG Stock Lonza Group AG
+47.19% 40.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.46% 38.62B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.79% 32.6B
CELLTRION, INC. Stock Celltrion, Inc.
-7.79% 27.49B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+17.93% 27.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+48.14% 14.61B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+40.66% 12.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.21% 11.36B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNFT Stock
  4. GNFT Stock
  5. Financials Genfit S.A.